Lowest-Rated StocksLowest-RatedNASDAQ:DOCS Doximity (DOCS) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free DOCS Stock Alerts $24.57 -0.22 (-0.89%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$24.56▼$25.1650-Day Range$24.63▼$30.3452-Week Range$19.71▼$37.06Volume1.36 million shsAverage Volume1.74 million shsMarket Capitalization$4.58 billionP/E Ratio37.23Dividend YieldN/APrice Target$28.82 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media Get Doximity alerts: Email Address Doximity MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside17.3% Upside$28.82 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 20 Articles This WeekInsider TradingSelling Shares$67,425 Sold Last QuarterProj. Earnings Growth6.94%From $0.72 to $0.77 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.20 out of 5 starsMedical Sector318th out of 910 stocksCustom Computer Programming Services Industry10th out of 23 stocks 3.0 Analyst's Opinion Consensus RatingDoximity has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 2 buy ratings, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageDoximity has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for DOCS. Previous Next 0.0 Dividend Strength Dividend YieldDoximity does not currently pay a dividend.Dividend GrowthDoximity does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for DOCS. Previous Next 2.5 News and Social Media Coverage News SentimentDoximity has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Doximity this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for DOCS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows12 people have added Doximity to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Doximity insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $67,425.00 in company stock.Percentage Held by Insiders39.40% of the stock of Doximity is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions87.19% of the stock of Doximity is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Doximity are expected to grow by 6.94% in the coming year, from $0.72 to $0.77 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Doximity is 37.23, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 141.61.Price to Earnings Ratio vs. SectorThe P/E ratio of Doximity is 37.23, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 218.35.Price to Earnings Growth RatioDoximity has a PEG Ratio of 3.10. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDoximity has a P/B Ratio of 4.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe #1 Crypto for 20245 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.Get His #1 Coin For 2024 FREE By Clicking Here About Doximity Stock (NASDAQ:DOCS)Doximity, Inc. operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers. It primarily serves pharmaceutical manufacturers and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.Read More DOCS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DOCS Stock News HeadlinesApril 3, 2024 | insidertrades.comKira Scherer Wampler Sells 2,500 Shares of Doximity, Inc. (NASDAQ:DOCS) StockApril 23, 2024 | businesswire.comDOCS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Doximity, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – DOCSApril 23, 2024 | Altimetry (Ad)Man Who Predicted 2008: “This Will be Worse.”He Was China's Second In Command – Then He Blew The Whistle Want to know what's really ahead for China's "economic miracle?" Beijing's second most powerful politician tried to warn us – and he may have paid with his life. And that's just one reason why the smart money is fleeing China for safer shores. U.S. Pentagon consultant Joel Litman has the full story – and a list of U.S. companies you'll want to buy now. April 23, 2024 | prnewswire.comIMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmApril 23, 2024 | markets.businessinsider.comINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoximityApril 22, 2024 | markets.businessinsider.comSHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmApril 22, 2024 | tmcnet.comDoximity, Inc. (DOCS) Investor Notice: Robbins LLP Reminds Stockholders of the Doximity, Inc. Shareholder Class ActionApril 22, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Doximity, Inc. - DOCSApril 23, 2024 | Altimetry (Ad)Man Who Predicted 2008: “This Will be Worse.”He Was China's Second In Command – Then He Blew The Whistle Want to know what's really ahead for China's "economic miracle?" Beijing's second most powerful politician tried to warn us – and he may have paid with his life. And that's just one reason why the smart money is fleeing China for safer shores. U.S. Pentagon consultant Joel Litman has the full story – and a list of U.S. companies you'll want to buy now. April 21, 2024 | americanbankingnews.comDoximity, Inc. (NASDAQ:DOCS) Given Consensus Rating of "Hold" by AnalystsApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCSApril 20, 2024 | prnewswire.comDOCS Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Doximity, Inc. (DOCS) that a Securities Fraud Class Action Lawsuit Has Been Filed On Their BehalfApril 20, 2024 | stockhouse.comDOCS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Doximity, Inc. Investors Can Join the Class Action Lawsuit!April 19, 2024 | businesswire.comDOXIMITY SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Doximity, Inc. - DOCSApril 19, 2024 | markets.businessinsider.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Doximity, Inc. with Losses to Contact the FirmApril 19, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Doximity, Inc. (DOCS) InvestorsApril 18, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Doximity, Inc. (DOCS)April 17, 2024 | businesswire.comInvestor Alert: Kessler Topaz Meltzer & Check, LLP Files a Securities Fraud Class Action Lawsuit Against Doximity, Inc. and Encourages Investors With Losses to Contact the Firm (NYSE: DOCS)April 16, 2024 | americanbankingnews.comAnalyzing TruBridge (NASDAQ:TBRG) and Doximity (NASDAQ:DOCS)April 12, 2024 | money.usnews.comDoximity Inc - Ordinary Shares - Class AApril 12, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCSApril 6, 2024 | stockhouse.comDoximity, Inc. (DOCS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsApril 5, 2024 | businesswire.comGlancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsApril 5, 2024 | businesswire.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsApril 5, 2024 | nasdaq.comInteresting DOCS Put And Call Options For March 2025April 4, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Doximity, Inc. - DOCSApril 3, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Announces Investigation of Doximity, Inc. (DOCS) on Behalf of InvestorsSee More Headlines Receive DOCS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Doximity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/08/2024Today4/23/2024Next Earnings (Estimated)5/21/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Custom computer programming services Sub-IndustryN/A Current SymbolNASDAQ:DOCS CUSIPN/A CIK1516513 Webwww.doximity.com Phone650-549-4330FaxN/AEmployees977Year FoundedN/APrice Target and Rating Average Stock Price Target$28.82 High Stock Price Target$33.00 Low Stock Price Target$23.00 Potential Upside/Downside+15.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.66 Trailing P/E Ratio37.94 Forward P/E Ratio34.78 P/E Growth3.1Net Income$112.82 million Net Margins29.39% Pretax Margin37.15% Return on Equity16.08% Return on Assets13.76% Debt Debt-to-Equity RatioN/A Current Ratio8.03 Quick Ratio8.03 Sales & Book Value Annual Sales$419.05 million Price / Sales11.15 Cash Flow$0.73 per share Price / Cash Flow34.29 Book Value$4.98 per share Price / Book5.03Miscellaneous Outstanding Shares186,550,000Free Float113,052,000Market Cap$4.67 billion OptionableNot Optionable Beta1.17 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Jeffrey A. Tangney (Age 51)Co-Founder, CEO & Chairperson Comp: $243.73kDr. Nate Gross M.D. (Age 40)Co-Founder & Chief Strategy Officer Comp: $455.54kMs. Anna Bryson (Age 34)Chief Financial Officer Comp: $453.71kMs. Jennifer W. Chaloemtiarana (Age 56)General Counsel & Corporate Secretary Comp: $504.04kMr. Paul Jorgensen (Age 53)Chief Revenue Officer Comp: $455.13kMs. Shari BuckCo-founder and SVP People & OpsMr. Jey BalachandranChief Technology OfficerMr. Perry Scott GoldHead of Investor RelationsJim RivasHead of Corporate CommunicationsMr. Bruno MirandaSenior VP of EngineeringMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLGlaukosNYSE:GKOSOrganon & Co.NYSE:OGNKrystal BiotechNASDAQ:KRYSHalozyme TherapeuticsNASDAQ:HALOView All CompetitorsInsiders & InstitutionsAmalgamated BankSold 8,084 shares on 4/23/2024Ownership: 0.036%Louisiana State Employees Retirement SystemBought 2,000 shares on 4/23/2024Ownership: 0.019%Sumitomo Mitsui Trust Holdings Inc.Bought 15,450 shares on 4/19/2024Ownership: 0.008%State of Michigan Retirement SystemBought 1,700 shares on 4/18/2024Ownership: 0.016%Oak Thistle LLCBought 12,004 shares on 4/18/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions DOCS Stock Analysis - Frequently Asked Questions Should I buy or sell Doximity stock right now? 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Doximity in the last twelve months. There are currently 2 sell ratings, 10 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" DOCS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DOCS, but not buy additional shares or sell existing shares. View DOCS analyst ratings or view top-rated stocks. What is Doximity's stock price target for 2024? 14 equities research analysts have issued twelve-month price objectives for Doximity's stock. Their DOCS share price targets range from $23.00 to $33.00. On average, they predict the company's stock price to reach $28.82 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price. View analysts price targets for DOCS or view top-rated stocks among Wall Street analysts. How have DOCS shares performed in 2024? Doximity's stock was trading at $28.04 at the beginning of 2024. Since then, DOCS shares have decreased by 12.4% and is now trading at $24.57. View the best growth stocks for 2024 here. When is Doximity's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our DOCS earnings forecast. How were Doximity's earnings last quarter? Doximity, Inc. (NASDAQ:DOCS) issued its earnings results on Thursday, February, 8th. The company reported $0.25 earnings per share for the quarter, topping analysts' consensus estimates of $0.19 by $0.06. The firm had revenue of $135.28 million for the quarter, compared to analysts' expectations of $127.46 million. Doximity had a trailing twelve-month return on equity of 16.08% and a net margin of 29.39%. What ETFs hold Doximity's stock? ETFs with the largest weight of Doximity (NASDAQ:DOCS) stock in their portfolio include Global X Telemedicine & Digital Health ETF (EDOC), Jacob Forward ETF (JFWD), Janus Henderson Small Cap Growth Alpha ETF (JSML), Fidelity Digital Health ETF (FDHT), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Renaissance IPO ETF (IPO), Pacer US Large Cap Cash Cows Growth Leaders ETF (COWG) and SPDR FactSet Innovative Technology ETF (XITK). What guidance has Doximity issued on next quarter's earnings? Doximity issued an update on its FY 2024 earnings guidance on Thursday, February, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $473.3 million-$474.3 million, compared to the consensus revenue estimate of $467.3 million. When did Doximity IPO? Doximity (DOCS) raised $501 million in an IPO on Thursday, June 24th 2021. The company issued 23,300,000 shares at $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs and J.P. Morgan Securities served as the underwriters for the IPO and Piper Sandler, William Blair, Canaccord and Raymond James were co-managers. Who are Doximity's major shareholders? Doximity's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Capital LLC (0.04%), Amalgamated Bank (0.04%), Apella Capital LLC (0.03%), Louisiana State Employees Retirement System (0.02%), State of Michigan Retirement System (0.02%) and RFG Advisory LLC (0.01%). Insiders that own company stock include Anna Bryson, Craig Overpeck, Gilbert H Kliman, Interwest Partners X Lp, Joseph B Kleine, Kevin Spain, Kira Scherer Wampler, Paul W Jorgensen and Timothy S Cabral. View institutional ownership trends. How do I buy shares of Doximity? Shares of DOCS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DOCS) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeHow to camouflage a factory of 53,000 workersStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Doximity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
